lobeglitazone

Lobeglitazone is an oral antidiabetic medication from the thiazolidinedione class. It acts as a dual agonist for peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ), functioning primarily as an insulin sensitizer. By activating these nuclear receptors in adipose tissue, lobeglitazone increases insulin sensitivity, reduces blood glucose levels, lowers hemoglobin A1C (HbA1C), and improves lipid and liver profiles. Compared to other thiazolidinediones like pioglitazone and rosiglitazone, lobeglitazone demonstrates higher affinity for PPARγ and is effective at lower doses with potentially fewer off-target effects. It was developed by Chong Kun Dang Pharmaceutical Corporation and approved in South Korea in 2013 for the treatment of type 2 diabetes mellitus[1][2][3][4][5][7].

Brand names

Duvie

Other names

lobeglitazonalobeglitazone sulfate